BDBM185149 1-[2-[5-[(3-methyloxetan-3-yl)methoxy]benzimidazol-1-yl]quinolin-8-yl]piperidin-4-amine::Crenolanib::US11542261, Compound crenolanib

SMILES CC1(COc2ccc3n(cnc3c2)-c2ccc3cccc(N4CCC(N)CC4)c3n2)COC1

InChI Key InChIKey=DYNHJHQFHQTFTP-UHFFFAOYSA-N

Data  15 IC50  18 Kd

PDB links: 4 PDB IDs match this monomer.

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 13 hits for monomerid = 185149   

TargetReceptor-type tyrosine-protein kinase FLT3(Human)
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM185149(1-[2-[5-[(3-methyloxetan-3-yl)methoxy]benzimidazol...)
Affinity DataKd:  0.200nMAssay Description:Table 8-10: Compounds were tested in 10-dose IC50 mode with 3-fold serial dilution starting at 10 uM, and are relative to DMSO, the negative control....More data for this Ligand-Target Pair
In DepthDetails US Patent

TargetReceptor-type tyrosine-protein kinase FLT3 [D835H](Human)
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM185149(1-[2-[5-[(3-methyloxetan-3-yl)methoxy]benzimidazol...)
Affinity DataKd:  0.200nMAssay Description:Table 8-10: Compounds were tested in 10-dose IC50 mode with 3-fold serial dilution starting at 10 uM, and are relative to DMSO, the negative control....More data for this Ligand-Target Pair
In DepthDetails US Patent

TargetReceptor-type tyrosine-protein kinase FLT3 [D835V](Human)
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM185149(1-[2-[5-[(3-methyloxetan-3-yl)methoxy]benzimidazol...)
Affinity DataKd:  0.0160nMAssay Description:Table 8-10: Compounds were tested in 10-dose IC50 mode with 3-fold serial dilution starting at 10 uM, and are relative to DMSO, the negative control....More data for this Ligand-Target Pair
In DepthDetails US Patent

TargetReceptor-type tyrosine-protein kinase FLT3 [D835Y](Human)
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM185149(1-[2-[5-[(3-methyloxetan-3-yl)methoxy]benzimidazol...)
Affinity DataKd:  0.190nMAssay Description:Table 8-10: Compounds were tested in 10-dose IC50 mode with 3-fold serial dilution starting at 10 uM, and are relative to DMSO, the negative control....More data for this Ligand-Target Pair
In DepthDetails US Patent

TargetDimer of Receptor-type tyrosine-protein kinase FLT3(Human)
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM185149(1-[2-[5-[(3-methyloxetan-3-yl)methoxy]benzimidazol...)
Affinity DataKd:  0.260nMAssay Description:Table 7 For most assays, kinase-tagged T7 phage strains were prepared in an E. coli host derived from the BL21 strain. E. coli were grown to log-phas...More data for this Ligand-Target Pair
In DepthDetails US Patent

TargetDimer of Receptor-type tyrosine-protein kinase FLT3 [D835V](Human)
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM185149(1-[2-[5-[(3-methyloxetan-3-yl)methoxy]benzimidazol...)
Affinity DataKd:  0.0230nMAssay Description:Table 7 For most assays, kinase-tagged T7 phage strains were prepared in an E. coli host derived from the BL21 strain. E. coli were grown to log-phas...More data for this Ligand-Target Pair
In DepthDetails US Patent

TargetDimer of Receptor-type tyrosine-protein kinase FLT3 [F691L](Human)
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM185149(1-[2-[5-[(3-methyloxetan-3-yl)methoxy]benzimidazol...)
Affinity DataKd:  0.110nMAssay Description:Table 7 For most assays, kinase-tagged T7 phage strains were prepared in an E. coli host derived from the BL21 strain. E. coli were grown to log-phas...More data for this Ligand-Target Pair
In DepthDetails US Patent

TargetReceptor-type tyrosine-protein kinase FLT3(Human)
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM185149(1-[2-[5-[(3-methyloxetan-3-yl)methoxy]benzimidazol...)
Affinity DataKd:  0.820nMAssay Description:Table 7 For most assays, kinase-tagged T7 phage strains were prepared in an E. coli host derived from the BL21 strain. E. coli were grown to log-phas...More data for this Ligand-Target Pair
In DepthDetails US Patent

TargetReceptor-type tyrosine-protein kinase FLT3 [N841I](Human)
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM185149(1-[2-[5-[(3-methyloxetan-3-yl)methoxy]benzimidazol...)
Affinity DataKd:  0.390nMAssay Description:Table 7 For most assays, kinase-tagged T7 phage strains were prepared in an E. coli host derived from the BL21 strain. E. coli were grown to log-phas...More data for this Ligand-Target Pair
In DepthDetails US Patent

TargetReceptor-type tyrosine-protein kinase FLT3 [R834Q](Human)
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM185149(1-[2-[5-[(3-methyloxetan-3-yl)methoxy]benzimidazol...)
Affinity DataKd:  1.30nMAssay Description:Table 7 For most assays, kinase-tagged T7 phage strains were prepared in an E. coli host derived from the BL21 strain. E. coli were grown to log-phas...More data for this Ligand-Target Pair
In DepthDetails US Patent

TargetReceptor-type tyrosine-protein kinase FLT3 [564-710,762-958](Human)
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM185149(1-[2-[5-[(3-methyloxetan-3-yl)methoxy]benzimidazol...)
Affinity DataKd:  17nMAssay Description:Table 7 For most assays, kinase-tagged T7 phage strains were prepared in an E. coli host derived from the BL21 strain. E. coli were grown to log-phas...More data for this Ligand-Target Pair
In DepthDetails US Patent

TargetInterleukin-1 receptor-associated kinase 1(Human)
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM185149(1-[2-[5-[(3-methyloxetan-3-yl)methoxy]benzimidazol...)
Affinity DataKd:  260nMAssay Description:Table 7 For most assays, kinase-tagged T7 phage strains were prepared in an E. coli host derived from the BL21 strain. E. coli were grown to log-phas...More data for this Ligand-Target Pair
In DepthDetails US Patent

TargetInterleukin-1 receptor-associated kinase 4(Human)
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM185149(1-[2-[5-[(3-methyloxetan-3-yl)methoxy]benzimidazol...)
Affinity DataKd:  62nMAssay Description:Table 8-10: Compounds were tested in 10-dose IC50 mode with 3-fold serial dilution starting at 10 uM, and are relative to DMSO, the negative control....More data for this Ligand-Target Pair
In DepthDetails US Patent